Rohto PharmaceuticalROHTO PHARMACEUTICAL CO.,LTD.4527東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

Rohto Pharmaceutical FY ending Mar 2026 results

About 49% of Rohto Pharmaceutical's sales come from Japan, with Asia and Europe making up much of the rest.

Out of every ¥100 of sales, about ¥12 is left as operating profit.

Revenue changed +11.4% from the prior year, operating profit +7.5%.

Revenue and profit pattern

Revenue and profit upRevenue grew faster

Revenue +11.4% · profit +7.5%, calculated from disclosed figures.

Operating leverage: 0.66× (profit growth ÷ revenue growth)

FY ending Mar 2025 → FY ending Mar 2026

Revenue for the FY ending Mar 2026 was ¥343.7B, up 11.4% from ¥308.6B.
Operating income grew more slowly, rising 7.5% to ¥41.1B, while net income attributable to owners rose 11.0% to ¥34.2B.
Operating cash flow jumped 29.4% to ¥47.8B, but free cash flow fell 18.3% to ¥21.5B.

Southeast Asian markets such as Vietnam and Indonesia stayed strong, and an import license in Myanmar let production restart there.
Adding Eu Yan Sang International of Singapore and Mono of Austria to the group boosted overseas sales.
In Japan, more inbound tourist demand and strong sales of lip balm, Hada Labo and eye drops lifted revenue, but a higher cost ratio held back profit, including in the UK after a container supplier went bankrupt.

Much of its sales come from overseas, so political and economic changes or currency swings in those countries could hurt results.
Rising raw material and energy prices or a supply chain shutdown could disrupt stable product supply.
Acquisitions and R&D spending may not pay off as planned, which could lead to impairment losses.

Annual securities report / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual securities report / 事業等のリスク

FY ending Mar 2025 → FY ending Mar 2026

For every ¥100 Rohto Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2026

Gross margin56.1%

Operating margin12.0%

Net margin10.0%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第90期(2025/04/01－2026/03/31)
ID S100YE5N2026-06-19Open
EDINET (FSA Japan)
訂正有価証券報告書－第89期(2024/04/01－2025/03/31)
ID S100WCHQ2025-07-11Open
EDINET (FSA Japan)
有価証券報告書－第88期(2023/04/01－2024/03/31)
ID S100TX7A2024-06-28Open
EDINET (FSA Japan)
有価証券報告書－第87期(2022/04/01－2023/03/31)
ID S100R8E42023-06-29Open
EDINET (FSA Japan)
有価証券報告書－第86期(令和3年4月1日－令和4年3月31日)
ID S100OFES2022-06-28Open
EDINET (FSA Japan)
有価証券報告書－第85期(令和2年4月1日－令和3年3月31日)
ID S100LOGZ2021-06-25Open

Extracted from XBRL: 56 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.